default author photo

Maria Alsina

Autonomous University of Barcelona - Institute of Oncology (VHIO)

Centro Cellex, Calle Natzaret, 115-117

Barcelona, 08035

Spain

SCHOLARLY PAPERS

2

DOWNLOADS

87

TOTAL CITATIONS

9

Scholarly Papers (2)

1.

Ramucirumab as First-Line Therapy in Combination with Cisplatin and Fluoropyrimidine in Patients with Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma (RAINFALL): A Global, Randomised, Double-Blinded, Placebo-Controlled, Phase 3 Trial

Number of pages: 228 Posted: 14 Sep 2018
Yale University, School of Medicine, Yale Cancer Center, National Cancer Center Hospital East, Fondazione IRCCS Istituto Nazionale dei Tumori, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), Krankenhaus Nordwest General Hospital - Institute of Clinical Cancer Research (ICCR), KU Leuven, Memorial Sloan Kettering Cancer Center, Autonomous University of Barcelona - Institute of Oncology (VHIO), NHS Foundation Trust - Royal Marsden Hospital, Yale University, School of Medicine, Yale Cancer Center, Université Paris XI Sud - Gustave Roussy Cancer Campus, Favaloro Foundation University Hospital, Center for Clinical Care and Research in Oncology (CAICO), Japanese Foundation for Cancer Research - Cancer Institute Hospital, The Christie NHS Foundation Trust, Harvard University - Gastrointestinal Cancer Treatment Center, N.N. Blokhin Russian Cancer Research Center, University of California, Los Angeles (UCLA) - UCLA Medical Center, HOPE—Practice for Oncology, Eli Lilly and Company, Ltd - Eli Lilly and Company, NYC, Eli Lilly and Company, Ltd - Eli Lilly and Company, Indianapolis, Eli Lilly Italia, S.p.A., Eli Lilly and Company, Ltd - Eli Lilly and Company, Indianapolis, Cornell University - Weill Cornell Medicine and Independent
Downloads 57 (989,921)
Citation 7

Abstract:

Loading...

2.

Cisplatin and 5-Fluorouracil with or Without Epidermal Growth Factor Receptor Inhibition Panitumumab for Patients with Non-Resectable, Advanced or Metastatic Esophageal Squamous Cell Cancer: A Prospective, Open-Label, Randomised Phase 3 AIO/EORTC Trial (Power)

Number of pages: 31 Posted: 17 Apr 2019
Johannes Gutenberg University Mainz - I. Med. Klinik und Poliklinik, Johannes Gutenberg University Mainz - I. Med. Klinik und Poliklinik, Charité - Universitätsmedizin Berlin, Tel Aviv University - Sackler Faculty of Medicine, University of Duisburg-Essen - University Hospital Essen, University Hospital Ulm, University of Mannheim, Krankenhaus Nordwest General Hospital - Institute of Clinical Cancer Research (ICCR), Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology, Onkologie Leer-Emden-Papenburg, Caritas Klinikum, University of Leipzig - Faculty of Medicine, Autonomous University of Barcelona - Institute of Oncology (VHIO), University of Rostock - University Medicine Rostock (UMR), Paracelsus Medical University Salzburg, Medical University of Innsbruck, Johannes Gutenberg University Mainz, Technische Universität München (TUM) - Institute of Pathology, KU Leuven and Technische Universität München (TUM)
Downloads 30 (1,318,317)
Citation 2

Abstract:

Loading...

esophageal squamous cell cancer, panitumumab, EGFR, palliative chemotherapy, cisplatin, 5-fluorouracil